Carbidopa News and Research

RSS
Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

Positive results from NeuroDerm ND0612 Phase I trial on Parkinson's

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

NeuroDerm initiates enrollment in ND0612 Phase I trial for Parkinson's

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

Levodopa/carbidopa intestinal gel reduces 'off' time in people with advanced PD

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

LCIG improves quality of life, reduces symptoms of Parkinson's

LCIG improves quality of life, reduces symptoms of Parkinson's

Impax announces data from IPX066 Phase III study on Parkinson's

Impax announces data from IPX066 Phase III study on Parkinson's

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Abbott reports positive results from LCIG Phase 3 trial for advanced Parkinson's disease

Levodopa-carbidopa intestinal gel better than standard oral form to treat advanced Parkinson's disease

Levodopa-carbidopa intestinal gel better than standard oral form to treat advanced Parkinson's disease

Impax announces FDA acceptance of NDA filing for IPX066

Impax announces FDA acceptance of NDA filing for IPX066

Impax submits IPX066 NDA to FDA for treatment of Parkinson's

Impax submits IPX066 NDA to FDA for treatment of Parkinson's

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

Positive results from NeuroDerm's ND0611 Phase I/II study for advanced Parkinson's disease

Michael J. Fox Foundation awards Impax $400,000 grant for research of IPX066 for Parkinson’s disease

Michael J. Fox Foundation awards Impax $400,000 grant for research of IPX066 for Parkinson’s disease

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Abbott reports positive interim results from LCIG Phase III open-label study for advanced Parkinson's disease

Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's

Impax announces results of IPX066 ADVANCE-PD and APEX-PD Phase III study against Parkinson's

APEX-PD Phase III clinical study data to be presented at American Academy of Neurology Conference

APEX-PD Phase III clinical study data to be presented at American Academy of Neurology Conference

Positive top-line results from IPX066 Phase III study in patients with PD

Positive top-line results from IPX066 Phase III study in patients with PD

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

GSK, Impax enter global development, commercialization agreement for PD investigational product, IPX066

GSK, Impax enter global development, commercialization agreement for PD investigational product, IPX066

Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease

Impax announces positive top-line results of Phase III IPX066 study for Parkinson's disease